Table 3.
The severest gastrointestinal (GI) symptoms for participants during each experimental trial.
| Participant | SBC2 | SBC3 | PLA |
|---|---|---|---|
| 1 | BUR (90.0)** | Vomiting (80.0)** | GF (39.0) |
| 2 | BUR (19.0) | GF (17.0) | GF (14.0) |
| 3 | Belching (20.0) | GF (18.0) | Belching (5.0) |
| 4 | GF (24.0) | GF (24.0) | Belching (23.0) |
| 5 | Nausea (31.0) | AD (33.0) | Nausea (23.0) |
| 6 | GF (59.0) | GF (59.0) | Belching (39.0) |
| 7 | GF (12.0) | GF (10.0) | Nil (0.0) |
| 8 | GF (39.0) | AD (31.0) | GF (69.0) |
| 9 | GF (10.0) | Flatulence (49.0) | Belching (21.0) |
| 10 | Flatulence (21.0) | AD (71.0) | AD (13.0) |
| 11 | Nil (0.0) | Nil (0.0) | Nil (0.0) |
| 12 | GF (17.0) | GF (72.0) | GF (66.0) |
Symptom scores (out of 100 mm) are displayed in parenthesis; SBC2, 0.2 g.kg−1 BM NaHCO3; SBC3, 0.3 g.kg−1 BM NaHCO3; PLA, sodium chloride (placebo); BUR, bowel urgency rating; GF, gut fullness; AD, abdominal discomfort;
**
Reported 5–10 min after laboratory visit; highest symptom severity for each participant highlighted in bold.